82 results about "Serum lipid levels" patented technology

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

This invention provides a *Lactobacillus plantarum* LN-Lp1 strain, its applications, products, and methods, belonging to the field of probiotic technology. The *Lactobacillus plantarum* LN-Lp1 strain has the accession number CGMCC 33158. This LN-Lp1 strain was deposited on December 23, 2024, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Based on this strain, this invention also provides its uses and related products. This LN-Lp1 strain exhibits strong resistance to simulated gastric-intestinal stress and good intestinal adhesion and colonization potential. The *Lactobacillus plantarum* LN-Lp1 of this invention has excellent weight-loss effects, improving lipid metabolism and lowering blood lipid levels.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The application relates to the technical field of microbial fermentation, and discloses a lily fermentation product for improving blood lipid, a preparation method and application thereof. Lily raw materials are taken as fermentation objects, and suitable lactobacillus plantarum fermentation strains are selected to ferment the lily raw materials to obtain a lily fermentation product. Compared with other fermentation products of lactobacillus plantarum, the lily fermentation product of the lactobacillus plantarum of CICC 25125 has more excellent pancreatic lipase inhibition capacity and has the effect of promoting and improving blood lipid levels, thereby providing a better basis for the application of the lily fermentation product in the food field.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

The invention relates to the technical field of biology, in particular to a probiotic composition for reducing blood sugar and application thereof.The probiotic composition comprises bifidobacterium longum subsp. Longum FMBL B241770LS and bifidobacterium animalis subsp. Lactis FMBL B24304AHDM which are preserved in the China Center for Type Culture Collection on September 21, 2024 with the preservation number of CCTCC NO: M 20241993 and preserved in the China Center for Type Culture Collection on November 18, 2024 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the the preservation number is CTCC (China Type Culture Collection) NO: M 20242505; the compound has a good inhibition effect on pathogenic bacteria, can obviously reduce oral glucose tolerance and insulin tolerance of T2DM mice, reduce abnormal fluctuation of postprandial blood glucose, reduce fasting blood glucose, fasting insulin level and blood fat level, relieve insulin resistance, effectively regulate intestinal flora imbalance and promote generation of short-chain fatty acid in intestinal tracts of the T2DM mice.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The invention discloses a low-energy wheat dietary fiber beverage and a preparation method thereof, wheat dietary fiber powder is used as a raw material, erythritol and stevioside are used as sweetening agents, konjaku flour is used as a natural thickening agent, and the wheat dietary fiber powder beverage is prepared through the links of blending, mixing, homogenizing, homogenizing, sterilizing and the like. The wheat dietary fiber beverage is mellow in taste and low in energy, can supplement enough dietary fibers for human bodies, has the functional characteristics of promoting digestion, controlling blood sugar and blood fat levels, resisting oxidation and the like, and can effectively solve the problems of poor drinking palatability, single taste and the like of wheat dietary fiber powder. The acceptability of the wheat dietary fiber powder is improved, and the requirements of the current public on sugar reduction and sugar control are met.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The invention relates to an application of oligosporine in preparation of a weight-reducing medicine. The invention finds that the oligosporine B can reduce the weight of mammals. Moreover, the further research finds that the weight loss of mammals can be realized due to the fact that triglyceride in fat cells is hydrolyzed into free fatty acid and glycerol by mainly enhancing the activity of a key rate-limiting enzyme responsible for lipid metabolism in the fat cells so as to reduce the blood fat level and lipid accumulation in the fat cells, so that the weight loss of the mammals can be realized. Therefore, the weight loss is realized by reducing the adipose tissue mass.

The application discloses a traditional Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: Radix Rehmanniae Preparata 12-15 parts, Cistanche 9-12 parts, Radix Astragali 12-15 parts, Cyperus rotundus 6-9 parts, Salvia miltiorrhiza 15-30 parts and safflower 6-9 parts. In addition, the application also relates to a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition has obvious effects of treating atherosclerosis, reducing homocysteine and blood lipid levels, improving patient symptoms and reducing atherosclerosis-related complications.

The present application mainly relates to a kind of composition for reducing fat and losing weight and its preparation method and application, belong to the field of biotechnology.The composition of the present application includes Cordyceps flower fruit body granules 30-60 parts, Morel fruit body granules 5-20 parts, bitter buckwheat flour 10-25 parts, mulberry leaf water extract 10-25 parts, Huangjing water extract 5-21 parts and Cassia seed water extract 1-6 parts.The above raw materials are mixed to obtain the composition of the present application.The composition of the present application can improve the blood lipid level of hyperlipidemia, inhibit the increase of body weight, reduce the volume of white adipose cells, inhibit the deposition of liver lipid, reverse the damage of liver tissue and liver function, effectively reduce fat and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The application discloses a medicine-food composition with the effects of improving blood sugar and blood fat, which is prepared from wolfberry leaves, wolfberry fruits, hawthorn fruits, jujube, white lentil and lotus leaves. Under the guidance of the theory of traditional Chinese medicine, dialectical treatment is adopted, the pathogenesis and pathogenic symptoms of hyperglycemia and hyperlipidemia are combined, and prescription screening is carried out. The experimental results show that the medicine-food composition can improve the blood sugar of a diabetic model rat, can regulate the blood fat level of the body, and has the advantages of good curative effect, good taste, low toxic and side effect, and clinical drug safety.

The invention relates to the field of food, in particular to meal replacement powder for reducing blood fat and preventing cardiovascular and cerebrovascular diseases. The meal replacement powder capable of reducing blood fat and preventing cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 30-45 parts of coix seed and red bean composite powder, 10-15 parts of konjac powder, 10-15 parts of oat bran, 15-20 parts of pumpkin seeds, 7-10 parts of black sesame, 5-15 parts of a mulberry leaf and hawthorn extract, 3-12 parts of corn resistant dextrin and 0.5-5 parts of composite prebiotics. According to the meal replacement powder capable of reducing blood fat and preventing cardiovascular and cerebrovascular diseases, through the synergistic effect of various natural components, the levels of total cholesterol, low-density lipoprotein cholesterol and triglyceride are remarkably reduced, meanwhile, the level of high-density lipoprotein cholesterol is improved, the meal replacement powder shows a remarkable blood fat reducing effect in SD rat experiments, and the meal replacement powder is suitable for being used for preventing cardiovascular and cerebrovascular diseases. Through the synergistic effect of various mechanisms of inhibiting cholesterol synthesis, promoting cholesterol discharge, improving intestinal health and the like, the blood fat level is effectively improved.

The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

The invention discloses an application of an REV-ERB alpha agonist SR9009 in preparation of a medicine for preventing and treating thoracic aortic aneurysm and dissection. The invention provides an application of an REV-ERB alpha agonist SR9009 in preparation of a medicine for preventing and / or treating thoracic aortic aneurysm and dissection. The step of preventing and treating the TAAD comprises the substeps of reducing the incidence rate of the TAAD and relieving cavities and / or fractures of the middle-layer structure of the thoracic aorta. Through intraperitoneal injection of the SR9009 in a TAAD mouse model, the result shows that the SR9009 can significantly reduce BAPN-induced mouse thoracic aorta VSMC apoptosis and elastic fiber degradation, and improve the histopathologic change of TAAD; the blood pressure, the body weight and the blood fat level of the mouse are not obviously influenced by the administration of the SR9009, and the SR9009 has good safety, so that the SR9009 provided by the invention has a good clinical application prospect.

The invention discloses an application of a BMAL1 activator ISX-9 in preparation of a medicine for preventing and treating thoracic aortic aneurysm and dissection. The invention provides an application of a BMAL1 activator ISX-9 in preparation of a medicine for preventing and / or treating thoracic aortic aneurysm and dissection. The step of preventing and treating the TAAD comprises the substeps of reducing the incidence rate of the TAAD and relieving cavities and / or fractures of the middle-layer structure of the thoracic aorta. According to the application disclosed by the invention, ISX-9 is subjected to intraperitoneal injection in a TAAD mouse model, and a result shows that the ISX-9 can be used for remarkably reducing BAPN-induced mouse thoracic aorta VSMC apoptosis and elastic fiber degradation and improving the histopathologic change of TAAD; the blood pressure, the body weight and the blood fat level of the mouse are not obviously influenced by the administration of the ISX-9, and the ISX-9 has good safety, so that the ISX-9 provided by the invention has a good clinical application prospect.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw material components in parts by mass: 8-10 parts of Guangxi curcuma zedoary, 8-12 parts of peach kernels, 8-12 parts of cassia twigs, 8-12 parts of poria cocos, 25-35 parts of raw astragalus membranaceus, 8-12 parts of moutan bark, 8-12 parts of red peony roots, 10-20 parts of fructus mali, 10-15 parts of herba lycopi and 25-35 parts of oysters. The traditional Chinese medicine composition can improve the lesion degree of atherosclerosis, reduce the blood fat level and reduce the generation of atheromatous plaques, thereby improving the atherosclerosis; meanwhile, the traditional Chinese medicine composition has an anti-AS effect in the aspects of stabilizing vulnerable plaques, promoting reverse transport of cholesterol, adjusting energy metabolism and water metabolism of mitochondria, resisting inflammation and resisting oxidative stress.

The invention provides gynura divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of polysaccharide preparation. The homogeneous component GDP1 of the gynura divaricata polysaccharide is mainly prepared from fructose, glucose, arabinose and galactose according to the molar ratio of 58.4: 39.08: 0.75: 0.78; the molecular weight Mw is 6684Da, and the purity is 99.04%; t2DM mouse in-vivo hypoglycemic activity research is carried out, and the prepared gynura divaricata polysaccharide can relieve the symptom of weight loss of mice, relieve the hyperglycemia and insulin resistance level of the mice and regulate the abnormal conditions of the blood fat level, the oxidative stress level and the inflammation level of the mice. The PI3K / Akt / GLUT-4 signal channel is activated to increase the glucose uptake of the T2DM mouse and reduce the insulin resistance of the T2DM mouse, so that the blood glucose metabolism of the T2DM mouse is improved. The gynura divaricata polysaccharide can be used for preparing medicines for treating type 2 diabetes mellitus.

The application provides a lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects and an application thereof, and belongs to the technical field of microorganisms. The lactobacillus sakei LN-Ls1 has a preservation number of CGMCC 30611. The LN-Ls1 strain is preserved in the China General Microbiological Culture Collection Center on May 13, 2024, and the address is No. 1, Beichen West Road, Chaoyang District, Beijing. Based on the strain, the application also provides the use and related products thereof. The lactobacillus sakei LN-Ls1 can significantly reduce body weight, improve blood lipid level and lipid metabolism without affecting food intake, has a remarkable weight loss and lipid-lowering effect, and has a better technical effect compared with existing products, and has good safety and application prospect.

The invention discloses an application of jujuboside A in preparation of an anti-atherosclerosis drug, which can significantly inhibit formation of atherosclerotic plaques, improve vascular functions and reduce blood fat level, has obvious effects, and is safe and reliable.

The invention discloses a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, and relates to the technical field of pharmacy, in particular to a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, the traditional Chinese medicine composition is prepared from the following raw material medicines: 100g of radix puerariae, 100g of herba epimedii, 100g of herba leonuri, 50g of dioscorea panthaica, 50g of raw endothelium corneum gigeriae galli, 50g of fructus aurantii immaturus, 50g of rhizoma dioscoreae nipponicae, 50g of lumbricus and 50g of kapok leaves. Pharmacodynamic tests prove that compared with related traditional Chinese medicine prescriptions in the prior art, the traditional Chinese medicine composition can significantly reduce the intima-media thickness of blood vessels, reduce the area proportion of plaques, improve the blood vessel stenosis rate, and improve the curative effect. 0.05 in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol), protecting vascular endothelial function (increasing the content of vascular endothelial relaxation factor NO and reducing endothelin ET level) and the like, and the pharmaceutical composition is superior to the prior art group (Plt: 0.05) in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride, low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol).